Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/precigen-to-present-late-breaking-abstract-for-pivotal-phase-2-study-data-for-prgn-2012-adenoverse-immunotherapy-for-the-treatment-of-patients-with-recurrent-respiratory-papillomatosis-at-the-2024-asco-annual-meeting-302125357.html
https://www.prnewswire.com/news-releases/precigen-reports-full-year-2023-financial-results-and-business-updates-302093363.html
https://www.prnewswire.com/news-releases/precigen-receives-orphan-drug-designation-for-prgn-2012-for-the-treatment-of-recurrent-respiratory-papillomatosis-from-the-european-commission-302035305.html
https://www.prnewswire.com/news-releases/precigen-highlights-pipeline-updates-to-be-presented-at-the-42nd-annual-jp-morgan-healthcare-conference-302027869.html
https://www.prnewswire.com/news-releases/precigen-reports-third-quarter-2023-financial-results-and-progress-of-clinical-programs-301983843.html
https://www.prnewswire.com/news-releases/precigen-to-participate-in-the-stifel-2023-healthcare-conference-301979276.html
https://www.prnewswire.com/news-releases/precigen-announces-fda-confirmation-that-the-ongoing-phase-12-study-of-prgn-2012-adenoverse-immunotherapy-will-serve-as-the-pivotal-study-to-support-accelerated-approval-301896509.html
https://www.prnewswire.com/news-releases/precigen-receives-breakthrough-therapy-designation-for-prgn-2012-adenoverse-immunotherapy-for-the-treatment-of-recurrent-respiratory-papillomatosis-301854546.html
https://www.clinicaltrialsarena.com/news/asco-2023-precigen-reports-positive-early-data-for-car-t-therapy/
https://www.prnewswire.com/news-releases/precigen-announces-positive-phase-1-data-for-prgn-3005-autologous-ultracar-t-cells-manufactured-overnight-for-infusion-next-day-to-advanced-stage-platinum-resistant-ovarian-cancer-patients-301842691.html